

FORM PTO-1390  
(REV. 7-2004)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTORNEY'S DOCKET NUMBER  
11183-003-999**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37CFR 1.5)

**10/524134**INTERNATIONAL APPLICATION NO.  
PCT/US03/25399INTERNATIONAL FILING DATE  
August 14, 2003PRIORITY DATE CLAIMED  
August 14, 2002

## TITLE OF INVENTION

FcGAMMA RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF

## APPLICANT(S) FOR DO/EO/US

Scott Koenig and Maria Concetta Veri

Applicant herewith submits to the United States Designated/ Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The U.S. has been elected (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US), but a courtesy copy is attached hereto
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration (executed) of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 20. below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute amendment.
16. ☒ A power of attorney by assignee and/or change of address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 37 CFR 1.821- 1.825.
18. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: copy of International Publication No. W0 2004/016750 A2, which is the publication of PCT/US03/25399; and copy of International Search Report; and copy of International Application PCT/US03/25399 as filed

US APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/524134		PCT/US03/25399		11183-003-999	
21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (A) (1) - (5)):					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....				\$1,110.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....				\$950.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....				\$790.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....				\$750.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	750.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$	.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE X		
Total Claims	110	90	\$50.00		4500.00
Independent Claims	28	25	\$200.00	=	5000.00
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 360.00	-	360.00
TOTAL OF ABOVE CALCULATIONS=				=	\$ 10,610.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				- \$	5305.00
SUBTOTAL =				\$	5305.00
Processing fee of \$130.00 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
TOTAL NATIONAL FEE				=	\$ 5305.00
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). x \$40.00 per property				\$	0.00
TOTAL FEES ENCLOSED				=	\$ 5305.00
				Amount to be refunded:	
				charged:	5305.00
a. <input type="checkbox"/> A check in the amount of \$0.00 to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge Deposit Account No. 50-3013 to cover the above fees. A copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3013. A copy of this sheet is enclosed.					
Note: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.					
22. <input type="checkbox"/> Other instructions					
23. <input checked="" type="checkbox"/> All correspondence for this application should be mailed to JONES DAY 20583					
24. <input type="checkbox"/> All telephone inquiries should be made to					
Margaret B. Brivanlou		Margaret B. Brivanlou		February 11, 2005	
NAME		SIGNATURE		DATE	
		40,258 40,922			
		REG. NO.			

**PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: KOENIG et al.

Confirmation No. To be assigned

Serial No.: To be assigned; National Stage  
Application of International  
Application No. PCT/US03/25399  
filed August 14, 2003

Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For: FC GAMMA RIIB SPECIFIC  
ANTIBODIES AND METHODS OF  
USE THEREOFAttorney Docket No. 11183-003-999  
(CAM: 505421-999002)**TRANSMITTAL**Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In connection with the filing of the above-identified application, transmitted herewith are the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (Form PTO-1390) (in duplicate);
2. Copy of the International Application as filed;
3. Copy of the International Publication WO 2004/016750 A2;
4. Copy of the International Search Report;
5. Transmittal of Declaration accompanied by Executed Declaration;
6. Transmittal of Sequence Listing under 37 C.F.R. §1.821;
7. Power of Attorney by Assignee and Exclusion of Inventor(s) under 37 C.F.R. §3.71 with Statement under 37 C.F.R. §3.73(b) executed by Michael Richman on behalf of MacroGenics, Inc. Mr. Richman is authorized to act on behalf of MacroGenics, Inc.
8. Copies of Assignment of the above-identified application to MacroGenics, Inc. which is concurrently submitted to the Assignment Recordation services for Recordation; and
9. Transmittal of Formal Drawings and 37 C.F.R. §§1.84 and 1.85 accompanied by Figures 1-16 (29 sheets).

This application is a National Stage Application of International Application No. PCT/US03/25399, filed August 14, 2003, which claims the benefit of U.S. Provisional Application No. 60/403,266 filed August 14, 2002.

Respectfully submitted,

Date: February 11, 2005

By: Margaret B. Brivanlou 40,258  
T.C. TSANG

Margaret B. Brivanlou

40,922

Reg. No.

**JONES DAY**

222 East 41st Street

New York, New York 10017

Telephone Number: 212-326-3939

Fax Nos.: (212) 755-7306

Enclosures

Express Mail No.: EV 452 774 625 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: KOENIG et al.

Confirmation No. To be assigned

Serial No.: To be assigned; National Stage  
Application of International  
Application No. PCT/US03/25399  
filed August 14, 2003

Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For: Fc GAMMA RIIB SPECIFIC  
ANTIBODIES AND METHODS OF  
USE THEREOFAttorney Docket No. 11183-003-999  
(CAM: 505421-999002)**TRANSMITTAL OF FORMAL DRAWINGS UNDER 37 C.F.R. §§1.84 AND 1.85**Commissioner For Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith twenty-nine (29) sheets of formal drawings of Figures 1(A-D), 2, 3, 4, 5(A-C), 6(A-B), 7(A-C), 8(A-C), 9(A-D), 10(A-G), 11(A-P), 12(A-B), 13(A-C), 14(A-T), 15(A-B), and 16 (A-C). The formal drawings are submitted in compliance with the requirements for formal drawings enumerated in 37 C.F.R. §§1.84 and 1.85.

No fee is believed due; however, should the Patent and Trademark Office determine otherwise, please charge the required fee to Deposit Account No. 50-3013.

Applicants respectfully request entry of the corrected formal drawings.

Date February 11, 2005

Respectfully submitted,

By: *T.C. Tsang* 40,258  
*Margaret B. Brivanlou* 40,922  
Margaret B. Brivanlou (Reg. No.)**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939

Enclosures

10/524134

DT05 PCT/PTO 11 FEB 2005

Express Mail No. EV 452 774 625 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	KOENIG et al.	Confirmation No.:	To be assigned
Serial No.:	To be Assigned (U.S. National Stage of PCT/US03/25399)	Art Unit:	To be assigned
Filed:	On Even Date Herewith	Examiner:	To be assigned
For:	Fc GAMMA RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF	Attorney Docket No:	11183-003-999
		(CAM:)	(505421-999002)

**TRANSMITTAL OF DECLARATION FOR  
NON-PROVISIONAL PATENT APPLICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith, in connection with the above-identified application, a Declaration for Non-Provisional Patent Application ("Declaration") executed by Scott Koenig and Maria Concetta Veri, as inventors of the above-identified application.

No fee is believed due with the filing of this Declaration. Should any fee be due, please charge the required fee to the Jones Day Deposit Account No. 503013.

Respectfully submitted,

by: *T.C. Tsang* 40,258  
T.C. TSANGDate: February 11, 2005

*Margaret B. Brivanlou* 40,922  
Margaret B. Brivanlou (Reg. No.)  
**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939